5 EASY FACTS ABOUT TRASTUZUMAB CHEMOTHERAPY DESCRIBED

Just about the most under-investigated “driving forces” linked to trastuzumab resistance is PTEN. Nagata et al. (2004) reported the lack of PTEN was observed in 36% of HER2-favourable Principal breast tumor specimens from individuals with phase IV illness. Furthermore, In addition they showed that clients with PTEN-deficient tumors experienced